10.6084/m9.figshare.9159530.v1 Frizziero M. Frizziero M. Spada F. Spada F. Lamarca A. Lamarca A. Kordatou Z. Kordatou Z. Barriuso J. Barriuso J. Nuttall C. Nuttall C. McNamara M.G. McNamara M.G. Hubner R.A. Hubner R.A. Mansoor W. Mansoor W. Manoharan P. Manoharan P. Fazio N. Fazio N. Valle J.W. Valle J.W. Supplementary Material for: Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas Karger Publishers 2019 Carboplatin-etoposide Extra-pulmonary neuroendocrine carcinoma Oral etoposide Intravenous etoposide 2019-07-29 14:28:32 Dataset https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Carboplatin_in_Combination_with_Oral_or_Intravenous_Etoposide_for_Extra-Pulmonary_Poorly-Differentiated_Neuroendocrine_Carcinomas/9159530 <b><i>Background:</i></b> Carboplatin-etoposide (CarboEtop) is a 1st-line option for patients with advanced extra-pulmonary (EP), poorly-differentiated (PD) neuroendocrine carcinoma (NEC). Different schedules are used in clinical practice and randomised evidence is lacking. <b><i>Objectives:</i></b> To provide real-life outcomes of carboplatin combined with oral or intravenous (IV) etoposide (Etop) in advanced EP-PD-NEC, from 2 specialist centres. <b><i>Methods:</i></b> Activity/efficacy/toxicity data of CarboEtop were collected retrospectively and analysed. <b><i>Results:</i></b> We identified 113 patients; median age: 65.8 years; male: 64%; gastro-entero-pancreatic origin: 54%; stage IV: 90%; median Ki-67: 70%; median follow-up: 11.5 months. A total of 123 courses of CarboEtop (oral: 45%; IV: 55%) were administered; 106 (86%) 1st-line, 16 (13%) 2nd-line, and 1 (1%) 3rd-line. Disease control rate: 74.5% in 1st-line and 69.2% in 2nd/3rd-line, with no significant difference between oral and IV Etop in 1st-line (69.8 vs. 80.8%, <i>p</i> = 0.237). Median progression-free survival (PFS): 6.0 and 4.5 months in 1st-line and 2nd/3rd-line, respectively. Overall survival (OS): 11.5 and 12.5 months in 1st-line and 2nd/3rd-line, respectively. The schedule (oral versus IV Etop) did not impact on 1st-line PFS (5.6 vs. 6.2 months, <i>p</i> = 0.179), although there was a trend towards shorter OS (8.9 vs. 12.1 months, <i>p</i> = 0.069). Liver metastases correlated with worse 1st-line PFS (<i>p</i> = 0.015) and 1st-line OS (<i>p</i> < 0.001) on multivariable analysis. The commonest grade 3–4 adverse event was myelosuppression (49%), with comparable toxicity between oral and IV Etop, except for venous thromboembolism (12.5 vs. 1.7%, <i>p</i> = 0.04). <b><i>Conclusions:</i></b> CarboEtop for advanced EP-PD-NEC is active, effective, and well-tolerated. Oral and IV Etop schedules are associated with comparable toxicity; activity should be compared in larger cohorts.